The Fall 2015 Oncology Stakeholders Summit, third in a series hosted by The American Journal of Managed Care, was moderated by Scott Gottlieb, MD, resident fellow at the American Enterprise Institute. Dr Gottlieb introduced the panel, which included John L. Fox, MD, MHA, senior medical director and associate vice president of Medical Affairs at Priority Health; Kavita Patel, MD, MS, non-resident senior fellow in Economic Studies at The Brookings Institution; and Ted Okon, executive director of Community Oncology Alliance.
Periostin Bests Eosinophil Count for Biomarker Predictability in ECRS
February 2nd 2023Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.
Read More
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
The Importance of Tailored Care Management Programs for High-risk Patients
September 20th 2022On this episode of Managed Care Cast, we speak with 2 authors of an article in the September issue of The American Journal of Managed Care®, which focused on the results of their evaluation of an intensive, community-based care management program for dual-eligible Medicaid ACO high-risk patients.
Listen
First Humira Biosimilar, Amjevita, Launches in the United States
January 31st 2023The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.
Read More
2 Clarke Drive
Cranbury, NJ 08512